We are live on ! Find out more
IBO

Impact BioMedical
IBO

20 hedge funds and large institutions have $2.23M invested in Impact BioMedical in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

208% more capital invested

Capital invested by funds: $726K → $2.23M (+$1.51M)

18.73% more ownership

Funds ownership: 11.82% → 30.55% (+19%)

17% less funds holding

Funds holding: 24 → 20 (-4)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
20
Holders Change
-4
Holders Change %
-16.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
1
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$559K
2
State Street
State Street
Massachusetts
+$298K
3
Northern Trust
Northern Trust
Illinois
+$117K
4
UBS Group
UBS Group
Switzerland
+$15.1K
5
GTAM
Global Trust Asset Management
Florida
+$909

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$69.6K
2
TSS
Two Sigma Securities
New York
-$11.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.33K
4
Jane Street
Jane Street
New York
-$7.11K
5
HF
HRT Financial
New York
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$716K +$559K +1,118,547 +1,504%
VCM
2
Vanguard Capital Management
Pennsylvania
$425K +$354K +708,168 New
State Street
3
State Street
Massachusetts
$365K +$298K +596,100 +5,053%
VFT
4
Vanguard Fiduciary Trust
Pennsylvania
$351K +$293K +585,198 New
BlackRock
5
BlackRock
New York
$156K – – –
Northern Trust
6
Northern Trust
Illinois
$146K +$117K +233,718 +2,286%
Two Sigma Investments
7
Two Sigma Investments
New York
$22.5K -$1.2K -2,400 -6%
UBS Group
8
UBS Group
Switzerland
$19.4K +$15.1K +30,248 +1,395%
VGA
9
Vanguard Global Advisers
Pennsylvania
$19.3K +$16.1K +32,201 New
MAC
10
Mason & Associates (California)
California
$5.85K – – –
Morgan Stanley
11
Morgan Stanley
New York
$5.56K +$4 +8 +0.1%
GTAM
12
Global Trust Asset Management
Florida
$1.09K +$909 +1,818 New
Citigroup
13
Citigroup
New York
$212 +$176 +352 +35,200%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$174 +$145 +290 New
Wells Fargo
15
Wells Fargo
California
$134 – – –
NFSG
16
Newbridge Financial Services Group
Florida
$52 – – –
Carson Wealth (CWM LLC)
17
Carson Wealth (CWM LLC)
Nebraska
$17 – – –
BH
18
Burk Holdings
Oklahoma
$16 +$13 +27 New
DB
19
Danske Bank
Denmark
$2 – – –
CFFP
20
Center for Financial Planning
Michigan
$1 – – –
Millennium Management
21
Millennium Management
New York
– -$69.6K -137,823 Closed
TSS
22
Two Sigma Securities
New York
– -$11.5K -22,695 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$8.33K -16,501 Closed
Jane Street
24
Jane Street
New York
– -$7.11K -14,086 Closed
HF
25
HRT Financial
New York
– -$6K -13,533 Closed
1
2

IBO Hedge Fund Activity: Q1 2026 in Review

20 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q1 2026, worth a combined $2.23M — up 208% from $726K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IBO and 6 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 6 added.

The largest buyer was Geode Capital Management, adding an estimated $559K. The largest seller was Millennium Management, exiting entirely with an estimated $69.6K sold.

  • 20 institutional investors held Impact BioMedical (IBO) as of Q1 2026, down from 24 in Q4 2025.
  • Funds reported $2.23M of Impact BioMedical stock for Q1 2026, up 208% quarter-over-quarter.
  • 6 funds opened new Impact BioMedical positions in Q1 2026 and 9 closed out, a net change of -3 holders.
  • The largest Impact BioMedical buyer in Q1 2026 was Geode Capital Management, an estimated $559K added.
  • The largest Impact BioMedical seller in Q1 2026 was Millennium Management, an estimated $69.6K sold.

Based on aggregated 13F filings for Q1 2026.